Search Results
Your search for ,foR matches 32412 pages
Showing 15601 - 15650ASH Honors Cage S. Johnson, MD, and José A. López, MD, With Award for Leadership in Promoting Diversity
DURING THE 2018 American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego this December, ASH will honor Cage S. Johnson, MD, Professor Emeritus of Medicine, Physiology, and Biophysics at the University of Southern California, and José A. López, MD, Professor of Medicine...
Lung Cancer Researcher Melissa Johnson, MD, Benefits From Father’s Perspective as Career Military Officer
Lung cancer researcher Melissa Johnson, MD, is a self-described “military brat,” whose father was a career officer in the Marine Corps, serving for more than 35 years. She was born in Oklahoma City and moved nine times during her childhood. When Dr. Johnson was in high school, her father was...
When Illness and Culture Collide
“‘Sickness’ is what is happening to the patient. Listen to him. Disease is what is happening to science and to populations.” —Lawrence Weed, MD, 1978 America’s massive health-care system is highly complex, with its own unique language, methods, technologies, and scientific approaches, developed and ...
Electronic ‘Datarrhea’ and Wellness
THE INTRODUCTION of the electronic health record (EHR) was supposed to lead us to a utopian world for health-care delivery in America. The Patient Protection and Affordable Care Act, signed into law on March 23, 2010, promoted its implementation by providing financial incentives.1 The Centers for...
A Career Path Shaped by Unlimited Possibilities for Clifford A. Hudis, MD, FACP, FASCO
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, interviewed Clifford A. Hudis, MD, FACP, FASCO, ASCO’s Chief Executive Officer. Prior to his current position, Dr. Hudis served in a variety of roles at ASCO, including President during ASCO’s 50th anniversary...
California Researchers Receive $4.5 Million to Develop Immunotherapies in Head and Neck Cancer
RESEARCHERS AT LA JOLLA INSTITUTE for Immunology and University of California (UC), San Diego, have been awarded $4.5 million as part of the National Cancer Institute’s Cancer Moonshot initiative. The funding will support research to develop new and improved immunotherapeutic options for patients...
The Abscopal Effect: A Reemerging Field of Interest
For the past 50 years or more, oncologists have designed their treatment plans around the three pillars: surgery, chemotherapy, and radiation. Now, with a series of recent successes, immunotherapy is rapidly reemerging as the fourth pillar in the oncologic armamentarium. Despite major advancements...
FDA Expands Approved Use of Brentuximab Vedotin in Some Types of PTCL
ON NOVEMBER 16, 2018, the U.S. Food and Drug Administration (FDA) expanded the approved use of brentuximab vedotin (Adcetris) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL)—adults with previously untreated systemic anaplastic...
2018 San Antonio Breast Cancer Symposium Award Winners Announced
THE SAN ANTONIO Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR) will honor three researchers for their work in breast cancer at the upcoming 2018 SABCS in December. They are Ian Smith, MD, FRCP, FRCPE, who will receive the SABCS William L. McGuire Memorial...
Iobenguane I-131 for Advanced Pheochromocytoma or Paraganglioma
ON JULY 30, 2018, the radiotherapeutic agent iobenguane I-131 (Azedra) was approved for the treatment of adult and pediatric patients (aged ≥ 12 years) with iobenguane scan–positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer...
FDA Approves Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
ON NOVEMBER 6, 2018, following Priority Review, the U.S. Food and Drug Administration (FDA) approved elotuzumab (Empliciti) injection for intravenous use in combination with pomalidomide (Pomalyst) and dexamethasone for the treatment of adult patients with multiple myeloma who have received at...
New Leadership Elected to ASH Executive Committee
THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) announced the election of four new members to its Executive Committee for terms beginning after the 2018 ASH Annual Meeting & Exposition in December. Martin S. Tallman, MD, will serve a 1-year term as Vice President, followed by successive terms as...
FDA Approves Glasdegib for Patients With Newly Diagnosed AML Who Cannot Undergo Intensive Chemotherapy
Today, the U.S. Food and Drug Administration (FDA) approved glasdegib (Daurismo) tablets to be used in combination with low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or with comorbidities that may preclude the use of ...
Chanita Hughes-Halbert, PhD, Receives AACR Distinguished Lecture on the Science of Cancer Health Disparities
Chanita Hughes-Halbert, PhD, is the recipient of the 2018 American Association for Cancer Research (AACR) Distinguished Lecture on the Science of Cancer Health Disparities, funded by Susan G. Komen. She was honored during the 11th AACR Conference on the Science of Cancer Health Disparities in...
Thank You From Conquer Cancer
When you give to ASCO’s Conquer Cancer Foundation, your donation provides grants to researchers around the world. Research fuels the breakthroughs in cancer prevention and treatment needed for every cancer, every patient, everywhere. “Year after year, we meet patients who credit their successful...
First Impressions Count: Share ASCO Resources With Your Newly Diagnosed Patients
Set new patients on the path to cancer education with ASCO Answers fact sheets. Choose from dozens of topics covering types of cancer, side effects, and treatments. ASCO Answers products ship for free inside the United States. ASCO members save 20%—browse titles and order a copy today on...
Pharmacy ‘Gag Clause’ Bills Signed Into Law
This past month, President Trump signed a pair of bills into law aimed at increasing transparency with regard to drug prices in the United States. The Patient Right to Know Drug Prices Act (S.2554) and the Know the Lowest Price Act (S.2553) prohibit so-called “gag clauses,” which prevent...
ASCO President-Elect Candidates Identify Key Issues Facing the Field of Oncology
Lori J. Pierce, MD, FASTRO, FASCO, of the University of Michigan, and Carolyn D. Runowicz, MD, FASCO, of Herbert Wertheim College of Medicine, Florida International University, Miami, were selected by the ASCO Nominating Committee as candidates for President-Elect. Why do you want to serve as ASCO...
ASCO, SITC Release Recommendations for Reporting of Immuno-Oncology Clinical Trials
ASCO and the Society for Immunotherapy of Cancer (SITC) have released a joint statement with 12 clinical trial reporting recommendations that address the unique efficacy, toxicity, and combination/sequencing aspects of immuno-oncology (IO) treatments. These recommendations, jointly published in the ...
2019 ASCO Election Candidates
The ASCO Nominating Committee has selected 15 distinguished ASCO members as candidates for open leadership positions within the Society, including: The office of President-Elect Three seats on the Society’s Board of Directors Three seats on the Nominating Committee Biographical information and...
Your Voice Matters: Vote in the ASCO Election by December 3
Each year, we call upon the ASCO members to place their votes to select our Society’s future leaders. This year, we are asking that you not only vote for the open leadership positions, but also for a proposed bylaw change. ASCO’s mission is more urgent than ever in today’s landscape of fast-moving ...
Cemiplimab-rwlc for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
On September 28, 2018, cemiplimab-rwlc (Libtayo) was approved for the treatment of patients with metastatic cutaneous squamous cell carcinoma or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.1 Supporting Efficacy Data Approval...
Patients With Cancer in Rural America Remain Underserved
Despite growing national awareness of health-care inequities, the plight of rural Americans diagnosed with cancer has persistently remained inadequate. Speaking with The ASCO Post, Jan Probst, PhD, Professor at the Arnold School of Public Health, University of South Carolina, Columbia, noted, “We...
Duvelisib in Resistant Chronic Lymphocytic Leukemia: Expanding the Treatment Armamentarium
The phase III DUO trial, reported by Flinn et al and reviewed in this issue of The ASCO Post, has led to the U.S. Food and Drug Administration (FDA) approval of a novel B-cell receptor (BCR) kinase inhibitor, duvelisib (Copiktra), which targets phosphoinositide 3-kinase (PI3K)-δ/γ in patients...
Duvelisib vs Ofatumumab in Relapsed or Refractory CLL/SLL
As reported in Blood by Ian W. Flinn, MD, PhD, Director of the Lymphoma Research Program at Sarah Cannon Research Institute, and colleagues, the phase III DUO trial has shown significantly prolonged progression-free survival with the phosphoinositide 3-kinase (PI3K)-δ/γ inhibitor duvelisib...
Parenteral Opioid Shortage Threatens Appropriate Pain Care for Patients With Cancer
In response to the opioid-overdose epidemic, several measures have been put in place, such as the reclassification of hydrocodone as a Schedule II opioid and new requirements for physician review of prescription drug–monitoring program databases in most states. Moreover, the Surgeon General and...
NCI Awards Grant to Team at Baylor to Establish Center to Focus on Cancer Health Disparities
As part of the Beau Biden Cancer Moonshot initiative, the National Cancer Institute has awarded $6.3 million to Nicholas Mitsiades, MD, of the Baylor College of Medicine, and a collaborative team at Baylor College of Medicine to establish a Minority Patient-Derived Xenograft Development and Trial...
UPMC Opens New Radiotherapy Center in Italy
The University of Pittsburg Medical Center (UPMC) recently announced the opening of a new radiotherapy center in Villa Maria, Italy, which will become part of the UPMC Hillman Cancer Center network when it opens to patients later this year. The new center, named the UPMC Hillman Cancer Center at...
Oncologist’s Research Recognized by Radiation Oncology Institute
Amar Kishan, MD, Assistant Professor of Radiation Oncology and a member of the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center, will receive the 2018 Publication Award from the Radiation Oncology Institute in recognition of a study highlighting the value of...
Inflammation, DNA Damage, and Cancer
The link between inflammation and cancer is a field of growing interest in the oncology community. Biologists have theorized that simultaneous DNA damage and cell division during inflammation could lead to cancer. To shed light on this important issue, The ASCO Post recently spoke with Jennifer...
Johns Hopkins Medicine Appoints Allen Kachalia, MD, JD, to Leadership Positions
Allen Kachalia, MD, JD, will be appointed Director of the Armstrong Institute for Patient Safety and Quality and Senior Vice President of Patient Safety and Quality for Johns Hopkins Medicine, starting December 1. During his nearly 20-year career in medicine, Dr. Kachalia has served in a variety...
Leukemia & Lymphoma Society Receives Funding for New Grants
The Leukemia & Lymphoma Society recently announced a $1,175,000 commitment by the Schwartz Ward Family Foundation of Chicago to support two research initiatives. These funds will support two grants in the society’s Career Development Program: Christiane Querfeld, MD, PhD, of City of Hope, is...
Global Liver Institute Supports More Frequent Liver Cancer Screening
When detected early, liver cancer is highly treatable and, in many cases, curable, yet the number of new cases of liver cancer in the United States has increased by 43% in the past 16 years, whereas the incidence of other cancers is on the decline. This past October, during Liver Cancer Awareness...
Dacomitinib for Metastatic EGFR-Mutant NSCLC
On September 27, 2018, dacomitinib (Vizimpro) received approval for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, as detected by a test approved by the...
FDA Approves Lorlatinib for Second- or Third-Line Treatment of ALK-Positive Metastatic NSCLC
On November 2, 2018, the U.S. Food and Drug Administration granted accelerated approval to lorlatinib (Lorbrena) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell lung cancer (NSCLC) whose disease has progressed on crizotinib (Xalkori) and at least one other ALK ...
Ibrutinib Plus Rituximab in Adult Patients With Waldenström’s Macroglobulinemia
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On August 27, 2018, ibrutinib (Imbruvica) was approved...
Undertreatment of High-Risk Prostate Cancer in Latino Men
New research by Lichtensztajn et al in JNCCN—Journal of the National Comprehensive Cancer Network examined disparities in care for Latino men with prostate cancer. A team of researchers from UCSF Helen Diller Family Comprehensive Cancer Center, Stanford Cancer Institute, and...
Azacitidine Plus Nivolumab in Relapsed or Refractory AML
A combination of the chemotherapy drug azacitidine with the immune checkpoint inhibitor nivolumab (Opdivo) demonstrated an encouraging response rate and overall survival in patients with relapsed or refractory acute myeloid leukemia (AML), according to findings from a phase II study published...
Neoadjuvant Chemotherapy vs Upfront Debulking Surgery in Advanced Tubo-Ovarian Cancer
As reported in The Lancet Oncology by Vergote et al, a pooled analysis of individual patient data in long-term follow-ups of the phase III EORTC 55971 and CHORUS trials indicated that overall survival is similar with neoadjuvant therapy vs upfront debulking surgery in advanced tubo-ovarian cancer....
Multimodality Therapy and Lateral Local Recurrence in Rectal Cancer
In a study reported in the Journal of Clinical Oncology, Ogura et al found that lateral lymph node dissection (LLND) reduced the risk of lateral local recurrence in patients with lateral nodes ≥ 7 mm undergoing neoadjuvant chemoradiation or radiation and total mesorectal excision in clinical...
Steven A. Rosenberg, MD, PhD, Works to Unmask Cancer’s Achilles Heel
Steven A. Rosenberg, MD, PhD, knew from the start of his medical career that if treatments for cancer were to become curative, research in new therapies would have to move away from the mainstay one-size-fits-all approach of systemic chemotherapy to an innovative, personalized strategy that...
Quality of Life With Postmastectomy Radiotherapy vs No Radiotherapy in Intermediate-Risk Breast Cancer
In a 2-year follow-up of the phase III SUPREMO trial reported in The Lancet Oncology, Galina Velikova, PhD, of the Leeds Cancer Centre, St. James’s University Hospital, United Kingdom, and colleagues found worse chest wall symptoms in women with intermediate-risk breast cancer who did vs did not...
ASTRO/ASCO/AUA Guideline for Early-Stage Prostate Cancer Supports Use of Hypofractionated Radiotherapy
Three prominent medical organizations have issued a new clinical guideline for physicians treating men with early-stage prostate cancer using external-beam radiation therapy (EBRT). Developed by a panel of experts from the American Society for Radiation Oncology (ASTRO), ASCO, and the American...
Atlantic Health System Announces Collaboration to Further Patient Access to Innovative Cancer Therapies
The Atlantic Health System, an integrated health-care delivery system, recently announced a partnership with the Translational Genomics Research Institute, an affiliate of City of Hope, and Origin Commercial Ventures to create a new platform to deliver economically viable immunotherapies and other...
Building Improved and Sustainable Health-Care Systems Through Telemedicine
Telemedicine—the remote diagnosis and treatment of patients via telecommunications technology—has changed the way oncology care is delivered in rural parts of the world. Patients in rural areas are now able to connect remotely with their physicians without having to deal with the time, expense, and ...
Heidi Nelson, MD, FACS, Named Medical Director of ACS Cancer Programs
The American College of Surgeons (ACS) announced that Heidi Nelson, MD, FACS, a colorectal surgeon at the Mayo Clinic in Rochester, Minnesota, will be joining the ACS Division of Research and Optimal Patient Care (DROPC) as Medical Director of Cancer Programs. Dr. Nelson comes to the ACS from her...
Allison S. Betof Warner, MD, PhD, on Managing Immune-Related Adverse Events: Incorporating Guidelines
Allison S. Betof Warner, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the rationale for immunotherapy and combination treatments, identifying the agents that lead to toxicities, and ways to manage them.
Charles von Gunten, MD, PhD, on Protecting Opioid Access for Patients in Need
Charles von Gunten, MD, PhD, of OhioHealth, discusses the critical need for opioids to manage cancer pain as well as the myth of addiction, which may impede best care.
Charles Gawad, MD, PhD, Receives NIH Director’s New Innovator Award
Charles Gawad, MD, PhD, an assistant member in the Departments of Oncology and Computational Biology at St. Jude Children’s Research Hospital, has been selected by the National Institutes of Health (NIH) to receive a Director’s New Innovator Award. Established in 2007, this award supports...
Modern Clinical Trials: Engaging Stakeholders at the Front Lines of Care
Randomized clinical trials have been providing high-quality evidence for decades, but there are limitations to the traditional design. At the 2018 ASCO Quality Care Symposium, George J. Chang, MD, MS, FACS, FASCRS, discussed the need to modernize clinical trials, so they continue to provide...
